Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT06418711 Not yet recruiting - Clinical trials for Mycobacterium Infections, Nontuberculous

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

ICoN-1
Start date: June 2024
Phase: Phase 3
Study type: Interventional

This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to Guideline-based therapy (GBT).

NCT ID: NCT06418048 Recruiting - Clinical trials for Infective Endocarditis

INfectious DIsease REgistry BIObank

INDI-REBIO
Start date: February 1, 2024
Phase:
Study type: Observational [Patient Registry]

Prospective observational study designed to describe the clinical, laboratory, imaging, microbiological characteristics and treatment of specific infectious diseases, with the addition of a dedicated biobank.

NCT ID: NCT06417983 Not yet recruiting - Fungal Infection Clinical Trials

Topical Application of Essential Oils to Treat Onchomycosis

NailFungus
Start date: May 30, 2024
Phase:
Study type: Observational

Patients with documented onychomycosis of one or more toe nails will be treated with a daily application of a topical lacquer containing several essential oils.

NCT ID: NCT06416709 Recruiting - Lung Injury Clinical Trials

Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases

Start date: May 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for Lung injury caused by major infectious diseases.

NCT ID: NCT06415474 Not yet recruiting - Clinical trials for Patients With Abdominal Infection

Evolution of the Lymphocyte Phenotype in Patients With Infection in Intensive Care Unit

REAPHEN
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Patients admitted for polytrauma, severe neurological injury, post-operative monitoring or sepsis/septic shock present with significant inflammation, leading to immunoparalysis, which is responsible for infection, particularly prolonged infection. A study of their lymphocyte phenotype over time could help explore the phenomenon of immunoparalysis.

NCT ID: NCT06413056 Completed - Neonatal Infection Clinical Trials

Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection

Start date: October 20, 2022
Phase: Phase 4
Study type: Interventional

The incidence of fungal infection has increased dramatically over the past few decades.This is due to increase in survival rates of preterm neonates, advances in medical technology and drug therapy, broad spectrum antibiotics and parenteral nutrition . The resistance to antifungal agents has increased. This study will assess the efficacy of micafungin versus amphotericin B in neonates with positive fungal culture.

NCT ID: NCT06412523 Active, not recruiting - Clinical trials for Central Nervous System Infections

Device-related Central Nervous System Infections in Adult Intensive Care Units in Brazil

IMPACTO-SNC
Start date: August 15, 2022
Phase:
Study type: Observational

Resistant microorganisms are public health problems because they affect the treatment of infectious diseases and the survival of patients. Neurosurgical procedures with placement of intracranial pressure monitoring and external ventricular drainage devices are related to increased morbidity and mortality. In Brazil, there are several multicenter studies demonstrating the prevalence and types of resistant microorganisms, however, there is a lack of data related to central nervous system infections associated with invasive devices, which can have a direct impact on prevention and treatment policies.

NCT ID: NCT06410053 Recruiting - Infectious Disease Clinical Trials

The All Ireland Infectious Diseases Cohort Project

AIID
Start date: March 2011
Phase:
Study type: Observational

The All-Ireland Infectious Diseases (AIID) Cohort is a multicentre, prospective, longitudinal observational cohort that enrols consecutive adult subjects attending participating institutions for infectious disease services. This is an ongoing prospective observational cohort of unlimited duration.

NCT ID: NCT06407232 Not yet recruiting - Clinical trials for Cytomegalovirus Infections

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Start date: May 2024
Phase: Phase 3
Study type: Interventional

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.

NCT ID: NCT06405958 Not yet recruiting - Clinical trials for Microbial Colonization

Gut Microbiome Analysis in Organ Transplant Recipient

Start date: May 1, 2024
Phase:
Study type: Observational

The microbiome acts as an antigen and can induce signaling through receptors like TLRs and NODs. Microbial metabolites can directly act on gut cells or reach other organs systemically. Studies show that the commensal, non-pathogenic microbiota plays an important role in regulating the immune system in various ways: - Promoting differentiation of Th17 cells and ILC3 signaling to regulate IL-17A production - Influencing iNKT cell generation early in life to prevent inflammatory activities - Facilitating CD4+ T cell differentiation and balancing Th1/Th2 responses - Inducing regulatory T cells (Tregs) that promote immune homeostasis - Tregs in Peyer's patches help maintain a microbiome that supports homeostasis The microbiome influences T cells, B cells and immune homeostasis. This has implications for transplantation, where modulating the microbiome could impact the graft's acceptance by affecting the recipient's immune cells that respond to the transplant. In summary, it highlights the microbiome's role in immune regulation and the potential for leveraging this interaction therapeutically, including in the context of transplantation.